Table 1. Clinicopathological parameters of subjects analyzed by miRNA microarray.
| Number | Case ID | Tumor type | Age (years) | UICC Stage | ER status | PR status | HER2/neu |
|---|---|---|---|---|---|---|---|
| 1 | 1 (T) | IDC | 33.3 | 2A | negative | negative | positive |
| 2 | 2 (N) | - | 31.8 | - | - | - | - |
| 3 | 2 (T) | IDC | 31.8 | 2A | positive | positive | negative |
| 4 | 3 (N) | - | 29.5 | - | - | - | - |
| 5 | 3 (T) | DCIS | 29.5 | 0 | positive | positive | negative |
| 6 | 4 (T) | IDC | 32.6 | 1 | negative | negative | positive |
| 7 | 5 (T) | DCIS | 28.6 | 0 | positive | positive | negative |
| 8 | 6 (N) | - | 35.1 | - | - | - | - |
| 9 | 8 (T) | IDC | 33.7 | 2A | positive | positive | negative |
| 10 | P (N) | - | - | - | - | - | - |
ID, identification; N, normal breast tissue; T, breast tumor; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; P, pooled normal sample; ER, estrogen receptor; PR, progesterone receptor; HER2/neu, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 receptors; UICC, stage of breast tumor according to the international union for cancer staging criteria.